News & Views | Published:

Immunotherapy

Cancer vaccine triggers antiviral-type defences

Nature volume 534, pages 329331 (16 June 2016) | Download Citation

An immunotherapy approach targets nanoparticles to dendritic cells of the immune system, leading to an antitumour immune response with antiviral-like features. Initial clinical tests of this approach show promise. See Letter p.396

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Nature 534, 396–401 (2016).

  2. 2.

    & Science 348, 74–80 (2015).

  3. 3.

    & Nature Rev. Cancer 12, 265–277 (2012).

  4. 4.

    et al. Cancer Res. 73, 1063–1075 (2013).

  5. 5.

    , , & Nature Rev. Immunol. 7, 790–802 (2007).

  6. 6.

    et al. J. Exp. Med. 196, 1627–1638 (2002).

  7. 7.

    et al. J. Exp. Med. 199, 815–824 (2004).

  8. 8.

    et al. Blood 106, 1278–1285 (2005).

  9. 9.

    et al. J. Control. Release 144, 118–126 (2010).

  10. 10.

  11. 11.

    et al. Gene Ther. 17, 961–971 (2010).

Download references

Author information

Affiliations

  1. Jolanda de Vries and Carl Figdor are in the Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands.

    • Jolanda De Vries
    •  & Carl Figdor

Authors

  1. Search for Jolanda De Vries in:

  2. Search for Carl Figdor in:

Corresponding authors

Correspondence to Jolanda De Vries or Carl Figdor.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nature18443

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing